Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Sep;81(2):269-76.
doi: 10.1038/sj.bjc.6690687.

Potent interaction of flavopiridol with MRP1

Affiliations
Free PMC article

Potent interaction of flavopiridol with MRP1

J H Hooijberg et al. Br J Cancer. 1999 Sep.
Free PMC article

Abstract

The multidrug resistance protein 1 (MRP1) is an ATP-dependent transport protein for organic anions, as well as neutral or positively charged anticancer agents. In this study we show that flavopiridol, a synthetic flavonoid currently studied in phase 1 trials for its antiproliferative characteristics, interacts with MRP1 in a potent way. Flavopiridol, as well as other (iso)flavonoids stimulate the ATPase activity of MRP1 in a dose-dependent way at low micromolar concentrations. A new specific monoclonal antibody against MRP1 (MIB6) inhibits the (iso)flavonoid-induced ATPase activity of plasma membrane vesicles prepared from the MRP1 overexpressing cell line GLC4/ADR. The accumulation of daunorubicin in GLC4/ADR cells is increased by flavopiridol and by other non-glycosylated (iso)flavonoids that interact with MRP1 ATPase activity. However, flavopiridol is the only tested compound that affects the daunorubicin accumulation when present at concentrations below 1 microM. Glycosylated (iso)flavonoids do not affect MRP1-mediated transport or ATPase activity. Finally, MRP1 overexpressing and transfected cells are resistant to flavopiridol, but not to other (iso)flavonoids tested. These findings may be of relevance for the development of anticancer therapies with flavopiridol.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Am J Clin Nutr. 1995 Dec;62(6):1276-82 - PubMed
    1. Bioessays. 1998 Nov;20(11):931-40 - PubMed
    1. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2735-40 - PubMed
    1. Cancer Res. 1996 Jul 1;56(13):2973-8 - PubMed
    1. Anticancer Drugs. 1995 Dec;6(6):727-35 - PubMed

Publication types

MeSH terms